Search

Your search keyword '"Turner, Hannah L."' showing total 3 results
Start Over Author "Turner, Hannah L." Publication Year Range This year
3 results on '"Turner, Hannah L."'

1. HIV BG505 SOSIP.664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodies

Author

Hahn, William O., primary, Parks, K. Rachael, additional, Shen, Mingchao, additional, Ozorowski, Gabriel, additional, Janes, Holly, additional, Ballweber-Fleming, Lamar, additional, Woodward-Davis, Amanda, additional, Duplessis, Chris, additional, Tomei, Mark, additional, Dey, Antu K., additional, Sagawa, Zachary K., additional, De Rosa, Stephen C., additional, Seese, Aaron, additional, Siddaramaiah, Latha Kallur, additional, Stamatatos, Leonidas, additional, Lee, Wen-Hsin, additional, Sewall, Leigh M., additional, Karlinsey, Dalton, additional, Turner, Hannah L., additional, Rubin, Vanessa, additional, Furth, Sarah, additional, MacPhee, Kellie, additional, Duff, Michael, additional, Corey, Lawrence, additional, Keefer, Michael C., additional, Edupuganti, Srilattha, additional, Frank, Ian, additional, Maenza, Janine, additional, Baden, Lindsey R., additional, Hyrien, Ollivier, additional, Sanders, Rogier W., additional, Moore, John P., additional, Ward, Andrew B., additional, Tomaras, Georgia D., additional, Montefiori, David C., additional, Rouphael, Nadine, additional, and McElrath, M. Juliana, additional

Published
2024
Full Text
View/download PDF

2. Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies

Author

Hahn, William O., Parks, K. Rachael, Shen, Mingchao, Ozorowski, Gabriel, Janes, Holly, Ballweber-Fleming, Lamar, Woodward Davis, Amanda S., Duplessis, Chris, Tomai, Mark, Dey, Antu K., Sagawa, Zachary K., De Rosa, Stephen C., Seese, Aaron, Kallur Siddaramaiah, Latha, Stamatatos, Leonidas, Lee, Wen-Hsin, Sewall, Leigh M., Karlinsey, Dalton, Turner, Hannah L., Rubin, Vanessa, Furth, Sarah, MacPhee, Kellie, Duff, Michael, Corey, Lawrence, Keefer, Michael C., Edupuganti, Srilatha, Frank, Ian, Maenza, Janine, Baden, Lindsey R., Hyrien, Ollivier, Sanders, Rogier W., Moore, John P., Ward, Andrew B., Tomaras, Georgia D., Montefiori, David C., Rouphael, Nadine, and McElrath, M. Juliana

Abstract

Stabilized trimers preserving the native-like HIV envelope structure may be key components of a preventive HIV vaccine regimen to induce broadly neutralizing antibodies (bnAbs). We evaluated trimeric BG505 SOSIP.664 gp140 formulated with a novel TLR7/8 signaling adjuvant, 3M-052-AF/Alum, for safety, adjuvant dose-finding, and immunogenicity in a first-in-healthy adult (n = 17), randomized, and placebo-controlled trial (HVTN 137A). The vaccine regimen appeared safe. Robust, trimer-specific antibody, and B cell and CD4+ T cell responses emerged after vaccination. Five vaccinees developed serum autologous tier 2 nAbs (ID50 titer, 1:28-1:8647) after two to three doses targeting C3/V5 and/or V1/V2/V3 Env regions by electron microscopy and mutated pseudovirus-based neutralization analyses. Trimer-specific, B cell–derived monoclonal antibody activities confirmed these results and showed weak heterologous neutralization in the strongest responder. Our findings demonstrate the clinical utility of the 3M-052-AF/Alum adjuvant and support further improvements of trimer-based Env immunogens to focus responses on multiple broad nAb epitopes.

Published
2024
Full Text
View/download PDF

3. HIV BG505 SOSIP.664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodies.

Author

Hahn WO, Parks KR, Shen M, Ozorowski G, Janes H, Ballweber-Fleming L, Woodward Davis AS, Duplessis C, Tomai M, Dey AK, Sagawa ZK, De Rosa SC, Seese A, Siddaramaiah LK, Stamatatos L, Lee WH, Sewall LM, Karlinsey D, Turner HL, Rubin V, Furth S, MacPhee K, Duff M, Corey L, Keefer MC, Edupuganti S, Frank I, Maenza J, Baden LR, Hyrien O, Sanders RW, Moore JP, Ward AB, Tomaras GD, Montefiori DC, Rouphael N, and McElrath MJ

Abstract

Stabilized trimers preserving the native-like HIV envelope structure may be key components of a preventive HIV vaccine regimen to induce broadly neutralizing antibodies (bnAbs). We evaluated trimeric BG505 SOSIP.664 gp140, formulated with a novel TLR7/8 signaling adjuvant, 3M-052-AF/Alum, for safety, adjuvant dose-finding and immunogenicity in a first-in-healthy adult (n=17), randomized, placebo-controlled trial (HVTN 137A). The vaccine regimen appeared safe. Robust, trimer-specific antibody, B-cell and CD4+ T-cell responses emerged post-vaccination. Five vaccinees developed serum autologous tier-2 nAbs (ID50 titer, 1:28-1:8647) after 2-3 doses targeting C3/V5 and/or V1/V2/V3 Env regions by electron microscopy and mutated pseudovirus-based neutralization analyses. Trimer-specific, B-cell-derived monoclonal antibody activities confirmed these results and showed weak heterologous neutralization in the strongest responder. Our findings demonstrate the clinical utility of the 3M-052-AF/alum adjuvant and support further improvements of trimer-based Env immunogens to focus responses on multiple broad nAb epitopes., Key Takeaway/take-Home Messages: HIV BG505 SOSIP.664 trimer with novel 3M-052-AF/alum adjuvant in humans appears safe and induces serum neutralizing antibodies to matched clade A, tier 2 virus, that map to diverse Env epitopes with relatively high titers. The novel adjuvant may be an important mediator of vaccine response.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results